Wells Megan, Hoffmann Jan, Stage Autumn, Enger Isabella, Pomper Jayme, Briggs Lily, LaCrosse Amber
Department of Psychology, Northern Michigan University, Marquette, Michigan.
Department of Psychology, Northern Michigan University, Marquette, Michigan.
J Pharmacol Exp Ther. 2025 Jan;392(1):100028. doi: 10.1124/jpet.124.002252. Epub 2024 Nov 22.
Post-traumatic stress disorder (PTSD) is caused by exposure to a traumatic or stressful event. Symptoms related to this disorder include persistent re-experiencing of memories and fear of generalization. Current pharmacological treatments for PTSD are insufficient, with fewer than 30% of patients reporting symptom remission. This study aims to determine the efficacy of acute (R,S)-ketamine and chronic fluoxetine (FLX) in reducing fear memory and fear generalization. In rodents, fear conditioning (FC) is commonly used in the literature to induce behaviors related to symptoms of PTSD, and the open field test (OFT) can assess anxiety and fear generalization behaviors during the exploration of a novel environment. In this study, FC consisted of a white noise cue stimulus and 4 inescapable foot shocks. Treatments began 4 hours after FC. Fear and anxiety behaviors were recorded during re-exposure to the FC stimuli at 24 hours and 2 weeks. The OFT was conducted 1 day before the last FC re-exposure. Results support the combined use of acute ketamine and chronic FLX as a treatment for reducing behaviors indicative of fear memory during re-exposure at 2 weeks, but not behaviors indicative of anxiety and fear generalization in the OFT. FLX alone was most effective in reducing behaviors related to fear generalization. This study contributes to the existing literature on pharmacological treatment for fear and anxiety behaviors relating to fear memory and fear generalization. Continued research is necessary to replicate results, optimize treatment protocols, and investigate the molecular adaptations to trauma and treatment. SIGNIFICANCE STATEMENT: Up to 6% of people in the United States will develop PTSD within their lifetime, and less than half of those individuals will find relief from their symptoms given the current therapeutic options. This study offers preliminary support for the efficacy of ketamine and FLX in reducing PTSD-like behaviors induced by fear-conditioning in mice. Compared with current standard treatments, the results of the current study indicate the potential for a more effective therapeutic option for those with stress-related disorders, such as PTSD.
创伤后应激障碍(PTSD)是由接触创伤性或应激性事件引起的。与该障碍相关的症状包括对记忆的持续重现和恐惧泛化。目前用于PTSD的药物治疗并不充分,报告症状缓解的患者不到30%。本研究旨在确定急性(R,S)-氯胺酮和慢性氟西汀(FLX)在减少恐惧记忆和恐惧泛化方面的疗效。在啮齿动物中,恐惧条件反射(FC)在文献中常用于诱导与PTSD症状相关的行为,而旷场试验(OFT)可在探索新环境期间评估焦虑和恐惧泛化行为。在本研究中,FC由白噪声线索刺激和4次不可逃避的足部电击组成。治疗在FC后4小时开始。在24小时和2周再次暴露于FC刺激期间记录恐惧和焦虑行为。OFT在最后一次FC再次暴露前1天进行。结果支持联合使用急性氯胺酮和慢性FLX作为一种治疗方法,以减少2周再次暴露时指示恐惧记忆的行为,但不能减少OFT中指示焦虑和恐惧泛化的行为。单独使用FLX在减少与恐惧泛化相关的行为方面最有效。本研究为现有关于与恐惧记忆和恐惧泛化相关的恐惧和焦虑行为的药物治疗文献做出了贡献。有必要继续进行研究以重复结果、优化治疗方案,并研究对创伤和治疗的分子适应性。意义声明:在美国,高达6%的人在其一生中会患上PTSD,而在目前的治疗选择下,这些人中不到一半会从症状中得到缓解。本研究为氯胺酮和FLX在减少小鼠恐惧条件反射诱导的PTSD样行为方面的疗效提供了初步支持。与当前的标准治疗相比,本研究结果表明,对于患有创伤后应激障碍等与压力相关疾病的人,有可能存在更有效的治疗选择。